Cellular vaccines and immunotherapeutics and methods for their preparation
AssigneeShanghai CP Guojian Pharmaceutical Co., Ltd.
InventorYajun Guo
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for enhancing the immunogenicity of weakly immunogenic or non-immunogenic cells, resulting in a cellular vaccine that can stimulate T cell activation, which in turn leads to an effective immune response. The cellular vaccines of the present invention are useful for the prevention and treatment of diseases which develop and/or persist by escaping the immune response triggered by T cell activation. Such diseases include, for example, all cancers, natural and induced immune deficiency states, and diseases caused by infections with a variety of pathogens.
Claims8
A method of preparing an immunogenic composition, comprising the steps of:
- (a) providing an autologous target tumor or pathogen infected cell;
- (b) treating the tumor or pathogen infected cell with IFN-γ and/or TNF-α to increase concentration of a primary T cell activation molecule or a costimulatory T cell activation molecule in the target tumor or pathogen infected cell;
- (c) providing a bispecific monoclonal antibody including one or more binding sites for one or more costimulatory molecules on a surface of one or more T cells of a patient mammal, wherein the bispecific antibody is a CD28:gp55 bispecific monoclonal antibody;
- (d) attaching the bispecific monoclonal antibody to the target tumor or pathogen infected cell;
- and
- (e) collecting a pharmaceutically effective amount of the target tumor or pathogen infected cell with the attached bispecific monoclonal antibody.
A method of preparing an immunogenic composition, comprising the steps of:
- (a) providing an autologous target tumor cell;
- (b) treating the tumor cell with IFN-γ and/or TNF-α to increase concentration of CD28 in the target tumor cell;
- (c) providing a CD28:gp55 bispecific monoclonal antibody;
- (d) attaching the CD28:gp55 bispecific monoclonal antibody to the target tumor cell;
- and
- (e) collecting a pharmaceutically effective amount of the target tumor cell with the attached CD2S:gp55 bispecific monoclonal antibody.
Dependencies are inferred from the claim text.